secwatch.observer — SEC 8-K summary
======================================

Issuer:     ABEONA THERAPEUTICS INC. (ABEO)
CIK:        0000318306
Form:       8-K
Filed at:   2024-11-12T23:59:59+00:00
Accession:  0001493152-24-044514
Event type: regulatory
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Abeona Therapeutics: FDA accepts BLA resubmission for pz-cel; PDUFA date April 29, 2025
--------------------------------------------------------------------------------

- FDA accepted for review Abeona's resubmitted BLA for pz-cel (autologous cell-based gene therapy for recessive dystrophic epidermolysis bullosa).
- PDUFA target action date assigned: April 29, 2025.
- Resubmission supported by Phase 3 VIITAL and Phase 1/2a data with up to 8 years of follow-up.
- If approved, pz-cel would be first autologous cell-based gene therapy for RDEB; Abeona may be eligible for a Priority Review Voucher.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/318306/000149315224044514/0001493152-24-044514-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/318306/000149315224044514/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-044514

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer